SEC Company Response from MEDICINOVA INC (MNOV) (CIK 0001226616) (MNOV) — Aug 18, 2006
MEDICINOVA INC (MNOV) (CIK 0001226616)
Date: Aug. 18, 2006 · CIK: 0001226616 · Accession: 0001193125-06-175961
AI Filing Summary & Sentiment
Reasoning
Letter
Letter to the SEC from the Company
[Letterhead of MediciNova, Inc.]
August 18, 2006
Via Edgar and Federal Express
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jeffrey P. Riedler, Assistant Director
Re: MediciNova, Inc. (the “Company”)
Amendment No. 1 to Schedule 14A
File No. 0-51133
Ladies and Gentlemen:
Pursuant to the letter from Mr. Riedler dated August 15, 2006 to Dr. Yuichi Iwaki, Chief Executive Officer of the Company, regarding the Preliminary Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company on August 9, 2006, the Company acknowledges the following with regard to the filing of the Proxy Statement and any amendments thereto:
•
the Company is responsible for the adequacy and accuracy of the disclosure in the Proxy Statement;
•
staff comments or changes to disclosure in response to staff comments do not foreclose the commission from taking any action with respect to the Proxy Statement; and
•
the Company may not assert staff comments as a defense in any proceeding initiated by the commission or any person under the federal securities laws of the United States.
Please do not hesitate to the undersigned, at (858) 373-1500, with any questions regarding this matter.
Very truly yours,
/s/ Shintaro Asako
Show Raw Text
CORRESP 1 filename1.htm Letter to the SEC from the Company [Letterhead of MediciNova, Inc.] August 18, 2006 Via Edgar and Federal Express U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: MediciNova, Inc. (the “Company”) Amendment No. 1 to Schedule 14A File No. 0-51133 Ladies and Gentlemen: Pursuant to the letter from Mr. Riedler dated August 15, 2006 to Dr. Yuichi Iwaki, Chief Executive Officer of the Company, regarding the Preliminary Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company on August 9, 2006, the Company acknowledges the following with regard to the filing of the Proxy Statement and any amendments thereto: • the Company is responsible for the adequacy and accuracy of the disclosure in the Proxy Statement; • staff comments or changes to disclosure in response to staff comments do not foreclose the commission from taking any action with respect to the Proxy Statement; and • the Company may not assert staff comments as a defense in any proceeding initiated by the commission or any person under the federal securities laws of the United States. Please do not hesitate to the undersigned, at (858) 373-1500, with any questions regarding this matter. Very truly yours, /s/ Shintaro Asako Shintaro Asako, Vice President, Accounting and Administration cc: Yuichi Iwaki, M.D., Ph.D. Mr. Gregory S. Belliston